source
- Beeline's oral lupus drug afimetoran meets primary endpoint in Phase 2, paving way for Phase 3Beeline Medicines announced that its oral small-molecule inhibitor afimetoran achieved the primary endpoint in a 48-week Phase 2 trial in patients with systemic lupus erythematosus (SLE). The tria…
- nPhase unveils AI-driven clinical data platform to accelerate trial design and submissionnPhase, a clinical research organization, announced the launch of an end-to-end platform called nPhase.ai that uses artificial intelligence to manage clinical trial data. The platform includes a S…